In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitrase Journal Ad Lacks Risk Information, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The violative ad for the spreading agent omits warnings, the Division of Drug Marketing, Advertising & Communications states.

You may also be interested in...



Catching DDMAC's Eye: Leaving Out Risk Information Proves Risky Practice For ISTA

ISTA receives a second warning letter from FDA in just over a year for promotional material that omits risk information for its lead ophthalmic product.

Catching DDMAC's Eye: Leaving Out Risk Information Proves Risky Practice For ISTA

ISTA receives a second warning letter from FDA in just over a year for promotional material that omits risk information for its lead ophthalmic product.

WLF’s “DDMAC Watch” Objects To Vitrase Ad Division Letter

Including the full risk information in the “brief summary” portion of promotional materials is sufficient, Washington Legal Foundation says.

Related Content

Topics

UsernamePublicRestriction

Register

PS061346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel